OS Therapies Inc

OSTX chart

OS Therapies Inc news

• OS Therapies Inc Stock Price Prediction: Today, Tomorrow, Next Week (OSTX)

  Traders Union · Oct 23, 12:03 PM EDT

• Maryland's OS Therapies Raises $7.2 Million to Advance Osteosarcoma Immunotherapy Toward Regulatory Review

  BioBuzz · Oct 22, 3:55 PM EDT

• OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

  Yahoo Finance · Oct 19, 8:30 AM EDT

• Rubenstein Public Relations Named Agency of Record for OS Therapies

  Yahoo Finance · Oct 8, 9:22 AM EDT

• OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

  Yahoo Finance · Oct 7, 8:30 AM EDT

• OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

  Yahoo Finance · Oct 6, 8:30 AM EDT

• OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

  Yahoo Finance · Oct 1, 8:30 AM EDT

• OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

  Yahoo Finance · Sep 24, 8:22 AM EDT

• OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

  Yahoo Finance · Sep 21, 6:30 AM EDT

• OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

  Yahoo Finance · Sep 17, 6:00 AM EDT

• OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

  Yahoo Finance · Sep 15, 7:46 AM EDT

• OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

  Yahoo Finance · Sep 8, 6:00 AM EDT

OS Therapies Inc key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 8-KCURRENT REPORT2026-10-19
• 8-KCURRENT REPORT2026-10-05
• 8-KCURRENT REPORT2026-09-10
• 8-KCURRENT REPORT2026-09-09
• 8-KCURRENT REPORT2026-08-21
• 10-QQUARTERLY REPORT2026-08-14
• 8-KCURRENT REPORT2026-08-12
• 8-KCURRENT REPORT2026-08-06
• 8-KCURRENT REPORT2026-07-29
• DEF 14APROXY STATEMENT2026-07-24
• 8-K/AAMENDMENT NO. 1 TO FORM 8-K2026-07-07
• 8-KCURRENT REPORT2026-07-02

About OS Therapies Inc

Ticker

OSTX (NYSE)

Industry

Pharmaceutical Preparations

Headquarters

Rockville, MD

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1795091

Frequently asked questions